Evaluation of the Effect of Systemic Proteolytic Enzyme Therapy on Postoperative Inflammatory Response and Quality of Life After Surgical Extraction of Impacted Mandibular Third Molars

To compare the postoperative pain between the patients who receive the systemic enzyme therapy and patients in the control group in the third and seventh day.
To compare the postoperative swelling (edema) between the patients who receive the systemic enzyme therapy and patients in the control group in the third and seventh day.
To compare the degree of trismus between the patients who receive the systemic enzyme therapy and patients in the control group in the third and seventh day.
Measure patients' perceptions of changes in their quality of life in the postoperative period and compare it between the patients who receive the systemic enzyme therapy and patients in the control group in the third and seventh day.

开始日期2024-05-08

申办/合作机构

University of Baghdad

NCT06319261 / Not yet recruitingN/AIIT

Efficacy of Guided Biofilm Therapy (GBT) for Treatment of Deep Periodontal Pockets: A Randomized Clinical Trial

the aim of the study is to evaluate the efficacy of guided biofilm therapy (GBT) for treatment of deep periodontal pockets.
the objectives are
1- To compare the change in the clinical periodontal parameters and microbiological parameters by using real time PCR for P. gingivalis, Aggregatibacter actinomycetemcomitans and Filifactor alocis among sites treated by GBT and conventional hand instrumentation after a period of 3 months and to assess the level of the selected periodontal pathogens in deep periodontal pockets and to estimate and compare deep periodontal pockets which need surgery after 3 months of non-surgical treatment by GBT and conventional hand instrumentation.
the hypothesis is whether there are no differences in in the clinical and microbiological parameters among sites treated by GBT and conventional hand instrumentation after a period of 3 months or there are differences in in the clinical and microbiological parameters among sites treated by GBT and conventional hand instrumentation after a period of 3 months.
The participants will be selected on a consecutive basis from patients referred to the Department of Periodontics, College of Dentistry, University of Baghdad.
For each patient, each site will be randomly assigned to either treatment protocol:
Sites treated with GBT.
Sites treated with conventional manual instrumentation only.

开始日期2024-04-01

申办/合作机构

University of Baghdad

100 项与 University of Baghdad 相关的临床结果

登录后查看更多信息

0 项与 University of Baghdad 相关的专利（医药）

登录后查看更多信息

17,884

项与 University of Baghdad 相关的文献（医药）

2025-02-01·Pharmaceutical Nanotechnology

Preparation, In-vitro, Ex-vivo, and Pharmacokinetic Study of Lasmiditan as Intranasal Nanoemulsion-based In Situ Gel

Article

作者: Rajab, Nawal A. ; Jaber, Saba Abdulhadi

Background:Lasmiditan (LAS) is a recently developed antimigraine drug and was approved in October, 2019 for the treatment of acute migraines; however, it suffers from low oral bioavailability, which is around 40%.Objective:This study aimed to improve the LAS bioavailability via formulation as nanoemulsionbased in situ gel (NEIG) given intranasally and then compare the traditional aqueous-LASsuspension (AQS) with the two successful intranasal prepared formulations (NEIG 2 and NEIG 5) in order to determine its relative bioavailability (F-relative) via using rabbits.Method:Two successfully prepared nanoemulsion (NE) formulas, a and b, were selected for the incorporation of different percentages of pH-sensitive in situ gelling polymer (Carbopol 934) to prepare NEIGs 1, 2, 3, 4, 5, and 6. The pH, gelation capacity, gel strength, and viscosity were predicted for the prepared NEIGs. The release (in vitro) and the nasal permeation (ex vivo) were determined for NEIG 2 and 5, and then both were subjected to pharmacokinetics in vivo studies. Eighteen male rabbits weighing 2.0 to 2.5 kg were employed in the parallel design study. The body surface area (BSA) normalization method was applied for LAS dose calculation. Serial blood samples were taken out and subjected to drug analysis using the HPLC method previously developed and validated by Kumar et al. Primary pharmacokinetics parameters, including maximum drug concentration in plasma (Cmax), time to reach C-max (T-max), and area under the concentration-time curve from time zero to affinity (AUCt0-∞) were calculated. Both NE (a and b), together with NEIG (2 and 5) formulas, were subjected to the stability study. Finally, a nasal ciliotoxicity study was carried out to evaluate the nasal toxicity of developed NEIGs 2 and 5.Result:The results showed that NEIGs 2 and 5 could be selected as the optimized NEIGs as both achieved 100% permeation within 20 min and then released within 25 and 35 min, respectively, thus achieving 3.3 folds with higher permeation percentages as compared to the AQS. Both NEIGs 2 and 5 exerted comparable release and permeation values as the corresponding NE a and b with more residence time in order to overcome the normal nasal physiological clearance. The values of C-max, Tmax, and AUC0- ∞ for NEIG 2 and NEIG 5 were 8066 ± 242 ng/ml, 0.75 ± 0.05 h, 19616.86 ± 589 ng. h/ml, and 7975.67 ± 239 ng/ml, 1.0 ± 0.05 h, 17912.36 ± 537 ng. h/ml, respectively, compared to the traditional AQS, which is equal to 4181.09 ± 125 ng/ml, 2 ± 0.2 h, and 8852.27 ± 266 ng. h/ml, respectively. It was discovered that NEIGs 2 and 5 had better intranasal delivery of LAS and could significantly (p < 0.05) achieve a higher value of permeability coefficient (3.3 folds) and 2.5 folds improvement in bioavailability when compared to AQS. The NE a, NE b, NEIG2, and NEIG5 formulations showed good stability at various temperatures. According to the nasal ciliotoxicity study, the nasal mucosal membrane, which was treated with NEIG 5, showed irritation with a bit of damage. However, damage was not observed when it was treated with NEIG 2, indicating the biocompatibility of the last one to be selected as the optimum formula.Conclusion:NEIG 2 and NEIG 5 are promising new intranasal formulas with a faster onset of action and greater bioavailability than the oral dosage form (AQS). Finally, the selected optimum gold formula that will be ready for further clinical study is NEIG 2.

2024-12-31·Egyptian Journal of Basic and Applied Sciences

Aging considerations of cytokines (IL-18, IL-36α, IL-37, and IL-38) associated with rheumatoid arthritis

作者: Ad’hiah, Ali H. ; Mahmood, Majid M. ; Abdul-Sahib, Nabaa S.

2024-12-31·Engineering Applications of Computational Fluid Mechanics

Computational analysis of turbulent flow characteristics in nanofluids containing 1-D and 2-D carbon nanomaterials: grid optimization and performance evaluation

作者: Shafik, Shafik S. ; Homod, Raad Z. ; Alzahrani, Hassan ; Klimova, Blanka ; Tao, Hai ; Alawi, Omer A. ; Togun, Hussein ; Mallah, Abdul Rahman ; Mohammed, Mustafa K. A. ; Yaseen, Zaher Mundher ; Aldlemy, Mohammed Suleman

项与 University of Baghdad 相关的新闻（医药）

2023-05-23

·BioSpace

Harbinger Health Appoints May Orfali, M.D. as Chief Medical Officer

Dr. Orfali brings over 25 years of experience across biopharma clinical development and medical practice Appointment comes at period of rapid growth as Harbinger prepares to complete enrollment for the CORE-HH clinical trial and meet other clinical and business milestones by end of 2023 CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ -- Harbinger Health, a biotechnology company pioneering the detection of early cancer, announced today the appointment of May Orfali, M.D., as Chief Medical Officer. Dr. Orfali will lead the Company's Cancer Origin Epigenetics – Harbinger Health (CORE-HH) clinical trial to advance clinical product development and evidence generation for Harbinger's novel platform technology. With more than 25 years of experience across the biopharma industry at companies such as Sigilon Therapeutics, Bioasis Technologies, and Pfizer, she will also charter Harbinger's clinical development program beyond CORE-HH and lay the foundations of commercial availability. Hutan Ashrafian, M.D., Ph.D., M.B.A., Harbinger's former Chief Medical Officer and current Chief Scientific Officer of Flagship Pioneering's Preemptive Medicine and Health Security Initiative, will continue to work closely with Dr. Orfali in a clinical advisory role. "May brings a wealth of experience in clinical product development and oncological care that will be invaluable to the advancement of our cancer origin epigenetics clinical trials," said Stephen Hahn, M.D., CEO of Harbinger Health. "Harbinger is in a period of rapid growth, and we are on target for our planned clinical milestones, including completion of enrollment of our CORE-HH study by year end. May's expertise will lead us in our next critical steps toward key milestones, with the ultimate goal making early cancer detection easier and more accessible to every patient. I also want to thank Hutan for spearheading our clinical team for the past 18 months and look forward to working with him as Harbinger continues to advance cancer detection." A hematology oncologist by training, Dr. Orfali most recently was the Chief Medical Officer at Sigilon Therapeutics. Prior to that, she was the Chief Medical Officer at CANbridge Life Sciences, where she led the clinical development and medical affairs group, focused on progressing Phase 1 and Phase II oncology assets in glioblastoma multiforme and esophageal cancer, and directed the medical review of business development opportunities in the rare disease space. Earlier in her career, Dr. Orfali held roles of increasing responsibility at Pfizer, including Executive Director, Global Product Development and Senior Director and Global Medical Lead/Medicines Development Group, Specialty Care Business Unit. "I am excited to take on this role during such an exciting time in Harbinger's growth, and work together with Harbinger's executive team and talented clinical organization," said Dr. Orfali. "The company's technology has the potential to meet a global unmet need and revolutionize how we approach cancer diagnosis, treatment, and preventative care." Dr. Orfali holds a medical degree from the University of Baghdad, Baghdad, Iraq, and a Pharmaceutical Master of Business Administration from Cambridge University, Cambridge, England. She completed her Fellowship in Pediatric Oncology and Hematology at Massachusetts General Hospital and Children's Hospital and practiced medicine and conducted clinical research in medical oncology at Dana Farber Cancer Research Institute. About Harbinger Health Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020. Learn more about Harbinger by visiting Harbinger-Health.com or following us on Twitter (@harbingerhlth) and LinkedIn. View original content to download multimedia: SOURCE Harbinger Health

高管变更临床1期临床2期

100 项与 University of Baghdad 相关的药物交易

登录后查看更多信息

100 项与 University of Baghdad 相关的转化医学

登录后查看更多信息